

## Brilliant Violet 650™ anti-mouse CD45.1 Antibody

<b>Catalog# / Size</b>	110735 / 125 µL 110736 / 50 µg
<b>Clone</b>	A20
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	T200, Ly-5.1, LCA
<b>Isotype</b>	Mouse (A.SW) IgG2a, κ
<b>Description</b>	CD45.1 is an alloantigen of CD45, expressed by Ly5.1 bearing mouse strains (e.g., RIII, SJL/J, STS/A, DA). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in mice that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell types. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Mouse
<b>Immunogen</b>	SJL mouse thymocytes and splenocytes
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
<b>Preparation</b>	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 650™ under optimal conditions.
<b>Concentration</b>	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.)
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	<p>Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a>. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.</p> <p>Brilliant Violet 650™ excites at 405 nm and emits at 645 nm. The bandpass filter 660/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. <b>Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.</b> Refer to your instrument manual or manufacturer for support. Brilliant Violet 650™ is a trademark of Sirigen Group Ltd.</p> <p><a href="#">Learn more about Brilliant Violet™.</a></p> <p>This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.</p>
<b>Excitation Laser</b>	Violet Laser (405 nm)

## Application Notes

The A20 antibody does not react with leukocytes or mouse cells expressing the CD45.2 alloantigen. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation<sup>3</sup>, *in vitro* blocking of B cell responses<sup>1,2</sup>, immunohistochemical staining of frozen sections: OCT embedded<sup>7</sup> and acetone-fixed<sup>4-6</sup> (direct immunofluorescence detection with fluorochrome conjugated A20 was used in (5) and (6)).

## Application References

(PubMed link indicates BioLegend citation)

1. Yakura H, *et al.* 1983. *J. Exp. Med.* 157:1077. (Block)
2. Yakura H, *et al.* 1986. *J. Immunol.* 136:2729. (Block)
3. Shen FW, *et al.* 1986. *Immunogenetics* 24:146. (IP)
4. Suzuki K, *et al.* 2000. *Immunity* 13:691. (IHC-F)
5. Werner N, *et al.* 2002. *Arterioscler. Thromb. Vasc. Biol.* 22:1567. (IHC-F)
6. Lessner SM, *et al.* 2002. *Am. J. Pathol.* 160:2145. (FC, IHC-F)
7. Chen CC, *et al.* 2005. *P. Natl. Acad. Sci. USA* 102:11408 (IHC-F)
8. Pascal V, *et al.* 2007. *J. Immunol.* 179:1751. (FC)
9. Mende I, *et al.* 2006. *Blood* 107:1383. (IHC-F, FC)
10. Phan TG, *et al.* 2007. *Nature Immunol.* 8:992. (FC)
11. Wither DR, *et al.* 2009. *J. Immunol.* 183:5079. [PubMed](#)
12. Pascal V, *et al.* 2007. *J. Immunol.* 179:1751. [PubMed](#)
13. Lee SW, *et al.* 2009. *J. Immunol.* 182:6753. [PubMed](#)
14. Takada K, *et al.* 2009. *J. Exp Med.* 206:2253. [PubMed](#)
15. Beamer CA, *et al.* 2007. *Am. J. Respir. Cell. Mol. Biol.* 37:729. (FC) [PubMed](#)
16. Li LX, *et al.* 2010. *J. Immunol.* 184:1728. [PubMed](#)
17. Hosoi A, *et al.* 2008. *Cancer Res.* 68:3941. (FC) [PubMed](#)
18. Kenna TJ, *et al.* 2008. *Blood* 111:2091. [PubMed](#)
19. Kohlmeier JE, *et al.* 2008. *Immunity.* 29:101. (FC) [PubMed](#)

## Product Citations

1. Doni A, *et al.* 2015. *J Exp Med.* 212:905. [PubMed](#)
2. Xu K, *et al.* 2021. *Immunity.* 54(5):976-987.e7. [PubMed](#)
3. Kobayashi T, *et al.* 2019. *Cell.* 176:982. [PubMed](#)
4. Su W, *et al.* 2020. *Cell Metabolism.* 32(6):996-1011.e7. [PubMed](#)
5. Di Genua C, *et al.* 2020. *Cancer Cell.* 37(5):690-704.e8. [PubMed](#)
6. Knizkova D, *et al.* 2022. *Nat Immunol.* 23:1644. [PubMed](#)
7. Fu G, *et al.* 2021. *Nature.* 595:724. [PubMed](#)
8. Schuldt N, *et al.* 2015. *PLoS One.* 10: 0145762. [PubMed](#)
9. Toomey CB, *et al.* 2018. *Invest Ophthalmol Vis Sci.* 59:662. [PubMed](#)
10. Toomey C, *et al.* 2015. *Proc Natl Acad Sci U S A.* 112:3040. [PubMed](#)
11. Janela B, *et al.* 2019. *Immunity.* 50:1069. [PubMed](#)
12. Baranwal G, *et al.* 2021. *Physiol Rep.* 9:e15094. [PubMed](#)
13. Verheijen M, *et al.* 2020. *Cell Rep.* 108376:33. [PubMed](#)
14. Loo CS, *et al.* 2020. *Immunity.* 53:143. [PubMed](#)
15. Youshani AS, *et al.* 2019. *J Neuroinflammation.* 16:25. [PubMed](#)
16. Di Genua C, *et al.* 2019. *Haematologica.* 104:2215. [PubMed](#)
17. Shi H, *et al.* 2020. *Immunity.* 51(6):1012-1027.e7. [PubMed](#)
18. Hogan T, *et al.* 2015. *Proc Natl Acad Sci U S A.* 112: 6917 - 6926. [PubMed](#)
19. Staffas A *et al.* 2018. *Cell host & microbe.* 23(4):447-457. [PubMed](#)
20. Shi H *et al.* 2018. *Immunity.* 49(5):899-914. [PubMed](#)
21. Jackson JT, *et al.* 2018. *Blood Adv.* 2:347. [PubMed](#)
22. Yáñez A *et al.* 2017. *Immunity.* 47(5):890-902. [PubMed](#)

## RRID

AB\_11124743 (BioLegend Cat. No. 110735)  
AB\_2562564 (BioLegend Cat. No. 110736)

## Antigen Details

---

<b>Structure</b>	Protein tyrosine phosphatase (PTP) family, 180-240 kD
<b>Distribution</b>	All hematopoietic cells except mature erythrocytes and platelets of the CD45.1 strain of mice
<b>Function</b>	Phosphatase, T and B cell activation
<b>Ligand/Receptor</b>	Galectin-1, CD2, CD3, CD4
<b>Biology Area</b>	Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"><li>1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press.</li><li>2. Trowbridge IS, <i>et al.</i> 1993. <i>Annu. Rev. Immunol.</i> 12:85.</li><li>3. Kishihara K, <i>et al.</i> 1993. <i>Cell</i> 74:143.</li><li>4. Pulido R, <i>et al.</i> 1988. <i>J. Immunol.</i> 140:3851.</li></ol>

## Gene ID

[19264](#)


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

Biotin anti-mouse CD45.1, FITC anti-mouse CD45.1, PE anti-mouse CD45.1, Purified anti-mouse CD45.1, APC anti-mouse CD45.1, APC/Cyanine7 anti-mouse CD45.1, Alexa Fluor® 488 anti-mouse CD45.1, Alexa Fluor® 647 anti-mouse CD45.1, Pacific Blue™ anti-mouse CD45.1, Alexa Fluor® 700 anti-mouse CD45.1, Brilliant Violet 650™ anti-mouse CD45.1, PerCP anti-mouse CD45.1, PerCP/Cyanine5.5 anti-mouse CD45.1, PE/Cyanine7 anti-mouse CD45.1, Brilliant Violet 421™ anti-mouse CD45.1, Brilliant Violet 570™ anti-mouse CD45.1, Brilliant Violet 605™ anti-mouse CD45.1, Brilliant Violet 711™ anti-mouse CD45.1, Brilliant Violet 510™ anti-mouse CD45.1, Brilliant Violet 785™ anti-mouse CD45.1, Purified anti-mouse CD45.1 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD45.1, Alexa Fluor® 594 anti-mouse CD45.1, APC/Fire™ 750 anti-mouse CD45.1, TotalSeq™-A0178 anti-mouse CD45.1, TotalSeq™-B0178 anti-mouse CD45.1, TotalSeq™-C0178 anti-mouse CD45.1

## Product Data



SJL mouse splenocytes were stained with CD45.1 (clone A20) Brilliant Violet 650™.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587